John F. Hardesty MD Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri.
Senior Lecturer, School of Public Health, University of Health and Allied Sciences, Ho, Ghana.
Mo Med. 2022 Jan-Feb;119(1):55-59.
Onchocerciasis is a parasitic disease that is the second most common cause of infectious blindness in the world, affecting 25 million people, mostly in sub-saharan Africa. Mass drug administration (MDA) with ivermectin has been the mainstay of a successful international effort to reduce the burden of vision loss. Despite improvements in infection rates and blindness through MDA with ivermectin, adult worms are not killed or permanently sterilized by this drug and can live for greater than 10 years. Therefore, new treatments for onchocerciasis are critical to accelerating the rate of elimination of this blinding disease. Here we discuss an ongoing study of a new treatment for onchocerciasis.
盘尾丝虫病是一种寄生虫病，是世界上第二大致盲的传染病，影响 2500 万人，主要在撒哈拉以南非洲。用伊维菌素进行大规模药物治疗（MDA）一直是减少失明负担的成功国际努力的基础。尽管通过 MDA 用伊维菌素改善了感染率和失明情况，但这种药物并不能杀死或永久杀死成虫，它们可以存活超过 10 年。因此，寻找盘尾丝虫病的新疗法对于加速消除这种致盲疾病至关重要。在这里，我们讨论一项新的盘尾丝虫病治疗方法的研究进展。
